Low-Dose Regional Citrate Anticoagulation Reduces Dialysis Filter Clotting, Suggests Study
A recent retrospective study published in the Indian Journal of Nephrology in January 2026 reveals that low-dose regional citrate anticoagulation (RCA) reduces dialysis filter clotting by 4.5 times in patients with acute-on-chronic liver failure (ACLF), safely prolonging circuit lifespans without triggering dangerous metabolic side effects.
While managing kidney complications in ACLF is notoriously difficult due to bleeding risks that typically discourage standard anticoagulants, a significant clinical gap remains regarding the safety of RCA in these fragile patients due to fears of citrate toxicity and a lack of data from emerging nations. To address this dearth of real-world evidence, researchers led by Chandani Bhagat at the Institute of Liver and Biliary Sciences Hospital in Delhi, India, aimed to retrospectively analyze the effectiveness and safety of RCA compared to no heparin during continuous kidney replacement therapy (CKRT).
Therefore, the retrospective study of 75 ICU patients with acute-on-chronic liver failure (ACLF) undergoing continuous veno-venous hemodiafiltration (CVVHDF) compared low-dose regional citrate anticoagulation (RCA, n=21) against no anticoagulation (n=54). Patients with pre-existing end-stage kidney disease were excluded. Using Cox regression analysis, the study primarily evaluated differences in filter lifespan, while secondarily assessing metabolic stability through changes in blood pH, ammonia, and lactate levels.
Key Clinical Findings of the Study Includes:
Filter Longevity: Researchers found that patients receiving no heparin required a significantly higher mean number of filters (2.56 ± 18) to maintain the circuit compared to the RCA group (1.5 ± 1.1).
Clotting Risk: Investigators established that avoiding anticoagulation entirely drastically increased the risk of filter clotting, demonstrating an adjusted hazard ratio of 4.5 when compared to the targeted low-dose RCA approach.
Metabolic Stability: Analysis confirmed that incorporating citrate did not introduce any statistically significant detrimental changes to pre- and post-therapy levels of serum ammonia, blood pH, or lactate between the two monitored cohorts.
Electrolyte Safety: Clinicians observed no episodes of severe hypocalcemia throughout the interventions, emphasizing the overall safety of the protocol when paired with rigorous calcium monitoring.
The results suggest that integrating a cautiously monitored, low-dose RCA protocol during continuous dialysis safely and significantly prolongs filter lifespan in highly susceptible ACLF patients. Ultimately, this targeted approach minimizes circuit downtime without adding dangerous metabolic complications to an already vulnerable clinical population.
Thus, the study concludes that critical care physicians might consider implementing low-dose citrate protocols to optimize dialysis efficiency for their complex liver failure patients in resource-restricted settings.
While the retrospective design, potential observer bias, and a relatively small sample size present certain constraints, it would be highly beneficial for future randomized controlled trials to gently explore various dosing and titration techniques to further refine this promising therapeutic approach.
Reference
Bhagat C, Meshram HS, Maiwall R, Mathur RP, Thakur AN, Puri S, et al. Regional Citrate Anticoagulation Compared With No Heparin in Continuous Renal Replacement Therapy Among Patients with Acute on Chronic Liver Failure. Indian J Nephrol. 2026;36:102-7.
